期刊
VACCINE
卷 28, 期 31, 页码 4937-4944出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.05.038
关键词
GM-CSF; TNF alpha; Therapeutic vaccine; Prostate cancer
资金
- Chinese National 863 plan [2006AA02Z4C4]
- Zhejiang Provincial Major Research Program [2008R10031, 2008C14082]
- Natural Science Foundation of Zhejiang Province [R2080407]
- Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents
- Wenzhou Municipal Research Program [G20090142]
A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNF alpha on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNF alpha-doubly surface-modified vaccine significantly extended the survival in the orthotopic model of RM-1 prostate cancer, and was superior to single GM-CSF- or TNF alpha-surface-modified vaccine. Moreover, the splenocytes from the GM-CSF/TNF alpha-vaccine-treated mice showed the most potent cytotoxicity on RM-1 cells and the highest production of RM-1-specific IFN gamma. In addition, more CD4(+) and CD8(+) T cells infiltrated into the tumor sites in the GM-CSF/TNF alpha-vaccine-treated mice than in the GM-CSF- or TNF alpha-vaccine-treated mice. Therefore, our study demonstrated that the efficacy of RM-1 prostate cancer cell vaccine could be improved by conjugating both GM-CSF and TNF alpha simultaneously on the surface of cancer cells, and that this modification thus has a potential translational significance. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据